These medicines have undergone rigorous clinical evaluation, have approved SmPCs, and are prescribed with appropriate monitoring and follow-up
Participants can receive standard of care therapies (defined as treatment with an approved AD medication, including an acetylcholinesterase inhibitor, memantine, or an anti-amyloid monoclonal antibody, or combinations of these agents) during the trial
Levels tend to me highest in kidney, liver, thymus, and spleen with slightly lower levels in lung, muscle, brain, and skin
it further reduced to 16.38 0.008% on the 4th day (Fig
It is administered through small subcutaneous injections
Contaminated, degraded, or underdosed peptides will not produce the effects described in the research literature